Formation Bio

Formation Bio is an AI-native pharmaceutical company that acquires clinical-stage drugs from pharmaceutical companies, universities and biotech firms and develops them using a proprietary technology platform. Founded in 2013, the company works across the full development lifecycle, from drug acquisition through to NDA submission, with the stated aim of bringing new treatments to patients faster and more efficiently.

The company's technology platform applies artificial intelligence and machine-learning methods to clinical drug development, covering areas such as trial design and data capture, trial execution and broader development optimisation. Its technical work spans artificial intelligence, machine learning and data-driven approaches, clinical trial technology, software engineering and drug development optimisation. Formation Bio began as TrialSpark, building clinical trial technology tools and operating as a contract research organisation, before shifting to acquire and develop its own portfolio of drugs; it adopted the Formation Bio name in December 2023 to reflect that expanded scope.

The engineering culture is described as combining expertise in drug selection and drug development with software engineering, with AI and data-driven methods integrated across the development lifecycle rather than applied to isolated tasks. The company positions itself at the intersection of scientific discovery and patient access, working on both the pharmaceutical and technology sides of drug development.